Consensus Ocugen, Inc.

Equities

OCGN

US67577C1053

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 11/04/2026 am IST			5-day change	1st Jan Change
1.760 ^USD	-5.88%		-1.68%	+30.37%

10/04	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
01/04	Ocugen Announces Early Completion of Dosing in Phase 2/3 Pivotal Confirmatory Trial of Ocu410st for Stargardt Disease	CI

Evolution of the Average Target: Ocugen, Inc.

Evolution of the Target Price: Ocugen, Inc.

Changes in Analyst Recommendations: Ocugen, Inc.

daef9a369e01.SzaBJTS2Et6Zcx8bF-TcXVW9bPDZj4514d4Kzq2alNk.O064FH_CVIfMRlNMcbSsaR3aC8Lo-9gPu69Zrej-pKsbBOlAUYFKt_Q3Xg~8bb12b44e3ccabbb224a9932b5cec192

Analysts' recommendations: Ocugen, Inc.

10/04	Ocugen, Inc. Announces Modifier Gene Therapy Delivers 46% Lesion Reduction in Age-Related Macular Degeneration	CI
17/03	Canaccord Genuity Initiates Ocugen at Buy With $12 Price Target	MT
11/03	Top Midday Gainers	MT
11/03	Oppenheimer Initiates Ocugen at Outperform With $10 Price Target	MT
06/25/06	Chardan Capital Adjusts Ocugen Price Target to $7 From $6, Maintains Buy Rating	MT
22/24/22	Chardan Adjusts Price Target on Ocugen to $5 From $4, Maintains Buy Rating	MT
22/24/22	Chardan Raises Price Target on Ocugen to $5 From $4, Keeps Buy Rating	MT
24/24/24	HC Wainwright Adjusts Price Target on Ocugen to $7 From $5, Maintains Buy Rating	MT
31/23/31	Cantor Fitzgerald Adjusts Ocugen's Price Target to $2 From $2.50, Keeps Overweight Rating	MT
08/23/08	Chardan Research Raises Ocugen's Price Target to $4 From $3.50, Buy Rating Kept	MT
01/23/01	Chardan Upgrades Ocugen to Buy From Neutral, Citing Recent Sell-Off	MT
01/23/01	Mizuho Adjusts Price Target on Ocugen to $3 From $5, Maintains Buy Rating	MT
23/22/23	Mizuho Securities Starts Ocugen at Buy With $5 Price Target	MT
15/22/15	HC Wainwright Adjusts Ocugen's Price Target to $6 from $7, Maintains Buy Rating	MT
15/22/15	Roth Capital Reinstates Ocugen at Buy with $8 Price Target	MT
02/22/02	Cantor Fitzgerald Starts Ocugen at Overweight With $4.50 Price Target	MT
09/22/09	Chardan Trims Ocugen's Price Targe to $3.50 From $4, Maintains Neutral Rating	MT
09/22/09	Chardan Research Adjusts Ocugen's Price Target to $3.50 From $4, Maintains Neutral Rating	MT
28/22/28	HC Wainwright Adjusts Ocugen's Price Target to $8 from $10, Maintains Buy Rating	MT
14/21/14	Analyst recommendations: Alliant Energy, Ally Financial, Alphabet, HSBC, Honest...
11/21/11	OCUGEN : Chardan Adjusts Ocugen PT to $4.50 From $8, Maintains Neutral Rating	MT
11/21/11	OCUGEN : Cantor Fitzgerald Adjusts Ocugen PT to $4 From $11, Maintains Neutral Rating	MT
11/21/11	OCUGEN : HC Wainwright Adjusts Ocugen's Price Target to $10 From $12, Maintains Buy Rating	MT
11/21/11	OCUGEN : Roth Capital Cuts Ocugen to Neutral From Buy, Price Target to $6 From $10	MT
10/21/10	OCUGEN : Chardan Adjusts Price Target on Ocugen to $8 From $13, Maintains Neutral Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	OCUGEN, INC.					+557.47%
	LONZA GROUP AG					+31.22%
	BEONE MEDICINES AG					+31.82%
	CELLTRION, INC.					+28.9%
	IQVIA HOLDINGS INC.					+38.79%
	REVOLUTION MEDICINES, INC.					+38.65%
	ASCENDIS PHARMA A/S					+22.91%
	MEDPACE HOLDINGS, INC.					+1.33%
	EUROFINS SCIENTIFIC SE					+11.99%
	Average					+84.79%
	Weighted average by Cap.					+30.32%